Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2024(Status and Outlook)
![](/report_cover/11711/global-glucagon-like-peptide-1-glp-1-based-therapies-market-research-report-2024status-n-outlook_en.gif)
Report Overview:
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size was estimated at USD 5721.97 million in 2023 and is projected to reach USD 7366.34 million by 2029, exhibiting a CAGR of 4.30% during the forecast period.
This report provides a deep insight into the global Glucagon-like peptide 1 (GLP-1)-based Therapies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Glucagon-like peptide 1 (GLP-1)-based Therapies market in any manner.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market Segmentation (by Type)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segmentation (by Application)
Hospital
Pharmacy
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size was estimated at USD 5721.97 million in 2023 and is projected to reach USD 7366.34 million by 2029, exhibiting a CAGR of 4.30% during the forecast period.
This report provides a deep insight into the global Glucagon-like peptide 1 (GLP-1)-based Therapies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Glucagon-like peptide 1 (GLP-1)-based Therapies market in any manner.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market Segmentation (by Type)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segmentation (by Application)
Hospital
Pharmacy
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market
- Overview of the regional outlook of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET COMPETITIVE LANDSCAPE
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2019-2024)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2019-2024)
3.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites, Area Served, Product Type
3.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.6.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.6.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES INDUSTRY CHAIN ANALYSIS
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Market Share by Type (2019-2024)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2019-2024)
7 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2019-2024)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2019-2024)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
8 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY REGION
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 North America
8.2.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novo Nordisk
9.1.1 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.1.4 Novo Nordisk Business Overview
9.1.5 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.1.6 Novo Nordisk Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 Eli Lily
9.3.1 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.3.5 Eli Lily Business Overview
9.3.6 Eli Lily Recent Developments
9.4 GSK
9.4.1 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.4.4 GSK Business Overview
9.4.5 GSK Recent Developments
9.5 Sanofi
9.5.1 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.5.4 Sanofi Business Overview
9.5.5 Sanofi Recent Developments
9.6 Bristol-Myers Squibb
9.6.1 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.6.4 Bristol-Myers Squibb Business Overview
9.6.5 Bristol-Myers Squibb Recent Developments
9.7 Abbott Laboratories
9.7.1 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.7.4 Abbott Laboratories Business Overview
9.7.5 Abbott Laboratories Recent Developments
10 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET FORECAST BY REGION
10.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
10.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
10.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2025-2030)
11.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) Forecast by Application
11.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET COMPETITIVE LANDSCAPE
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2019-2024)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2019-2024)
3.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites, Area Served, Product Type
3.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.6.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.6.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES INDUSTRY CHAIN ANALYSIS
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Market Share by Type (2019-2024)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2019-2024)
7 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2019-2024)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2019-2024)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
8 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY REGION
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 North America
8.2.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novo Nordisk
9.1.1 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.1.4 Novo Nordisk Business Overview
9.1.5 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.1.6 Novo Nordisk Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 Eli Lily
9.3.1 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
9.3.5 Eli Lily Business Overview
9.3.6 Eli Lily Recent Developments
9.4 GSK
9.4.1 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.4.4 GSK Business Overview
9.4.5 GSK Recent Developments
9.5 Sanofi
9.5.1 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.5.4 Sanofi Business Overview
9.5.5 Sanofi Recent Developments
9.6 Bristol-Myers Squibb
9.6.1 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.6.4 Bristol-Myers Squibb Business Overview
9.6.5 Bristol-Myers Squibb Recent Developments
9.7 Abbott Laboratories
9.7.1 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
9.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
9.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
9.7.4 Abbott Laboratories Business Overview
9.7.5 Abbott Laboratories Recent Developments
10 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET FORECAST BY REGION
10.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
10.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
10.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2025-2030)
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2025-2030)
11.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) Forecast by Application
11.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Comparison by Region (M USD)
Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2022)
Table 10. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites and Area Served
Table 12. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (Kilotons)
Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Type (2019-2024)
Table 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
Table 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Type (2019-2024)
Table 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Share by Type (2019-2024)
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (USD/Ton) by Type (2019-2024)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Application
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2024)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2024) & (M USD)
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2024)
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
Table 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2024)
Table 38. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 43. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 44. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 45. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novo Nordisk Business Overview
Table 47. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 48. Novo Nordisk Recent Developments
Table 49. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 50. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 51. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 54. AstraZeneca Recent Developments
Table 55. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 56. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 57. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 59. Eli Lily Business Overview
Table 60. Eli Lily Recent Developments
Table 61. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 62. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 63. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. GSK Business Overview
Table 65. GSK Recent Developments
Table 66. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 67. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 68. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sanofi Business Overview
Table 70. Sanofi Recent Developments
Table 71. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 72. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 73. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Recent Developments
Table 76. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 77. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 78. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Abbott Laboratories Business Overview
Table 80. Abbott Laboratories Recent Developments
Table 81. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2030) & (Kilotons)
Table 82. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2030) & (M USD)
Table 83. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 84. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 85. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 86. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 87. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2030) & (Kilotons)
Table 88. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2030) & (M USD)
Table 89. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 90. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 91. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Forecast by Country (2025-2030) & (Units)
Table 92. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 93. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2025-2030) & (Kilotons)
Table 94. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2030) & (M USD)
Table 95. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2025-2030) & (USD/Ton)
Table 96. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) Forecast by Application (2025-2030)
Table 97. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Comparison by Region (M USD)
Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2022)
Table 10. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Sites and Area Served
Table 12. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (Kilotons)
Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Type (2019-2024)
Table 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2019-2024)
Table 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Type (2019-2024)
Table 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Share by Type (2019-2024)
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (USD/Ton) by Type (2019-2024)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) by Application
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2024)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2019-2024) & (M USD)
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2024)
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
Table 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2024)
Table 38. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2019-2024) & (Kilotons)
Table 43. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 44. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 45. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novo Nordisk Business Overview
Table 47. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 48. Novo Nordisk Recent Developments
Table 49. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 50. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 51. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 54. AstraZeneca Recent Developments
Table 55. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 56. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 57. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies SWOT Analysis
Table 59. Eli Lily Business Overview
Table 60. Eli Lily Recent Developments
Table 61. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 62. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 63. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. GSK Business Overview
Table 65. GSK Recent Developments
Table 66. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 67. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 68. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Sanofi Business Overview
Table 70. Sanofi Recent Developments
Table 71. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 72. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 73. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Recent Developments
Table 76. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Basic Information
Table 77. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 78. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Abbott Laboratories Business Overview
Table 80. Abbott Laboratories Recent Developments
Table 81. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2030) & (Kilotons)
Table 82. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2030) & (M USD)
Table 83. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 84. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 85. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 86. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 87. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2025-2030) & (Kilotons)
Table 88. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2025-2030) & (M USD)
Table 89. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2025-2030) & (Kilotons)
Table 90. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 91. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Forecast by Country (2025-2030) & (Units)
Table 92. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2025-2030) & (M USD)
Table 93. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2025-2030) & (Kilotons)
Table 94. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2025-2030) & (M USD)
Table 95. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2025-2030) & (USD/Ton)
Table 96. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) Forecast by Application (2025-2030)
Table 97. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD), 2019-2030
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) (2019-2030)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (M USD)
Figure 11. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2023
Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2023
Figure 13. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type
Figure 18. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2024)
Figure 19. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 20. Market Size Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2024)
Figure 21. Market Size Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application
Figure 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2024)
Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application in 2023
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2024)
Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2023
Figure 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
Figure 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2024)
Figure 30. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 32. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 37. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 44. China Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 50. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 51. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Type (2025-2030)
Figure 65. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2025-2030)
Figure 66. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD), 2019-2030
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) (2019-2030)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (M USD)
Figure 11. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2023
Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2023
Figure 13. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type
Figure 18. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2024)
Figure 19. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 20. Market Size Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2019-2024)
Figure 21. Market Size Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application
Figure 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2019-2024)
Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application in 2023
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2019-2024)
Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2023
Figure 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2019-2024)
Figure 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2019-2024)
Figure 30. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 32. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 37. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 44. China Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 50. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2023
Figure 51. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Type (2025-2030)
Figure 65. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2025-2030)
Figure 66. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Application (2025-2030)